par Piccart-Gebhart, Martine 
Référence Annals of oncology, 12 Suppl 1, page (S89-S94)
Publication Publié, 2001
Référence Annals of oncology, 12 Suppl 1, page (S89-S94)
Publication Publié, 2001
Article révisé par les pairs
| Titre: |
|
| Auteur: | Piccart-Gebhart, Martine |
| Informations sur la publication: | Annals of oncology, 12 Suppl 1, page (S89-S94) |
| Statut de publication: | Publié, 2001 |
| Sujet CREF: | Sciences bio-médicales et agricoles |
| Mots-clés: | Anti-HER2 monoclonal antibody |
| HER2 | |
| Herceptin | |
| Predictive marker | |
| Prognostic marker | |
| Trastuzumab | |
| Treatment guidelines | |
| MeSH keywords: | Antibodies, Monoclonal -- therapeutic use |
| Antineoplastic Agents -- therapeutic use | |
| Breast Neoplasms -- chemistry | |
| Breast Neoplasms -- drug therapy | |
| Breast Neoplasms -- pathology | |
| Clinical Trials as Topic | |
| Europe | |
| Female | |
| Humans | |
| Practice Guidelines as Topic | |
| Predictive Value of Tests | |
| Prognosis | |
| Receptor, erbB-2 -- analysis | |
| Risk Factors | |
| Tumor Markers, Biological -- analysis | |
| Note générale: | Journal Article |
| Research Support, Non-U.S. Gov't | |
| Review | |
| SCOPUS: ar.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0923-7534 |
| info:doi/10.1093/annonc/12.suppl_1.S89 | |
| info:pii/S0923753419544647 | |
| info:scp/0034878178 | |
| info:pmid/11521728 |
